Literature DB >> 1749054

Toxic neonatal effects following maternal clomipramine therapy.

M S Schimmell1, E Z Katz, Y Shaag, A Pastuszak, G Koren.   

Abstract

Clomipramine is a chlorinated tricyclic antidepressant commonly used in the treatment of depression (1). The drug is widely prescribed in Europe and Canada and has been recently approved for use in the USA. Its safety during pregnancy and breastfeeding, however, has not been fully established. Very few reports on its effect on the fetus and neonate have been published (2,3). We report a case of a mother treated with clomipramine during pregnancy, and the side effects observed in the infant. The correlation between plasma clomipramine concentrations in the baby's blood and clinical effects are described. Subsequently, we present the pregnancy outcome of five prospectively collected cases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1749054     DOI: 10.3109/15563659109025744

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  18 in total

Review 1.  Depression in childbearing women: when depression complicates pregnancy.

Authors:  Sheila M Marcus; Julie E Heringhausen
Journal:  Prim Care       Date:  2009-03       Impact factor: 2.907

Review 2.  Prenatal antidepressant exposure: clinical and preclinical findings.

Authors:  Chase H Bourke; Zachary N Stowe; Michael J Owens
Journal:  Pharmacol Rev       Date:  2014-02-24       Impact factor: 25.468

3.  The inhibition characteristics of human placental glutathione S-transferase-π by tricyclic antidepressants: amitriptyline and clomipramine.

Authors:  Ozlem Dalmizrak; Gulnihal Kulaksiz-Erkmen; Nazmi Ozer
Journal:  Mol Cell Biochem       Date:  2011-05-13       Impact factor: 3.396

Review 4.  Treating mood disorders during pregnancy: safety considerations.

Authors:  Malin Eberhard-Gran; Anne Eskild; Stein Opjordsmoen
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

5.  Sleep-related epilepsy in a Long-Evans hooded rat model of depression.

Authors:  Angela L McDowell; Kingman P Strohl; Pingfu Feng
Journal:  Sleep Breath       Date:  2011-12-29       Impact factor: 2.816

Review 6.  Benefits and risks to mother and infant of drug treatment for postnatal depression.

Authors:  Shaila Misri; Xanthoula Kostaras
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

7.  Clomipramine concentration and withdrawal symptoms in 10 neonates.

Authors:  Peter G J ter Horst; Susanne van der Linde; Jan Pieter Smit; Jan den Boon; Richard A van Lingen; Frank G A Jansman; Lolkje T W De Jong-van den Berg; Bob Wilffert
Journal:  Br J Clin Pharmacol       Date:  2012-02       Impact factor: 4.335

Review 8.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 9.  [Gender differences in psychopharmacology].

Authors:  V Regitz-Zagrosek; C Schubert; S Krüger
Journal:  Internist (Berl)       Date:  2008-12       Impact factor: 0.743

10.  When depression complicates childbearing: guidelines for screening and treatment during antenatal and postpartum obstetric care.

Authors:  Maria Muzik; Sheila M Marcus; Julie E Heringhausen; Heather Flynn
Journal:  Obstet Gynecol Clin North Am       Date:  2009-12       Impact factor: 2.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.